2026-04-18T07:53:06Zhttps://recercat.cat/oai/request

oai:recercat.cat:2072/4747202025-08-31T17:04:48Zcom_2072_98col_2072_378192

Quality of Life and the Experience of Living with Early-Stage Alzheimer's Disease Villarejo-Galende, Alberto García-Arcelay, Elena Piñol-Ripoll, Gerard Del Olmo-Rodríguez, Antonio Viñuela, Félix Boada, Mercè Franco-Macías, Emilio Ibañez De La Peña, Almudena Riverol, Mario Puig-Pijoan, Albert Abizanda-Soler, Pedro Arroyo, Rafael Baquero-Toledo, Miquel Feria-Vilar, Inmaculada Balasa, Mircea Berbel, Ángel Rodríguez-Rodríguez, Eloy Vieira-Campos, Alba García-Ribas, Guillermo Rodrigo-Herrero, Silvia Terrancle, Ángeles Prefasi, Daniel Lleó, Alberto Maurino, Jorge Universitat Autònoma de Barcelona Alzheimer's disease Amyloid Biomarkers Cerebrospinal fluid Magnetic resonance imaging Tau proteins White matter hyperintensities White matter lesions Background: There is a need to better understand the experience of patients living with Alzheimer's disease (AD) in the early stages. Objective: The aim of the study was to evaluate the perception of quality of life in patients with early-stage AD. Methods: A multicenter, non-interventional study was conducted including patients of 50-90 years of age with prodromal or mild AD, a Mini-Mental State Examination (MMSE) score ≥22, and a Clinical Dementia Rating-Global score (CDR-GS) of 0.5.-1.0. The Quality of Life in Alzheimer 's Disease (QoL-AD) questionnaire was used to assess health-related quality of life. A battery of self-report instruments was used to evaluate different psychological and behavioral domains. Associations between the QoL-AD and other outcome measures were analyzed using Spearman's rank correlations. Results: A total of 149 patients were included. Mean age (SD) was 72.3 (7.0) years and mean disease duration was 1.4 (1.8) years. Mean MMSE score was 24.6 (2.1). The mean QoL-AD score was 37.9 (4.5). Eighty-three percent (n = 124) of patients had moderate-to-severe hopelessness, 22.1% (n = 33) had depressive symptoms, and 36.9% (n = 55) felt stigmatized. The quality of life showed a significant positive correlation with self-efficacy and negative correlations with depression, emotional and practical consequences, stigma, and hopelessness. Conclusion: Stigma, depressive symptoms, and hopelessness are frequent scenarios in AD negatively impacting quality of life, even in a population with short disease duration and minimal cognitive impairment. 2022 Article https://ddd.uab.cat/record/290594 urn:10.3233/JAD-220696 urn:oai:ddd.uab.cat:290594 urn:scopus_id:85141935081 urn:articleid:18758908v90n2p719 urn:pmid:36155523 urn:pmc-uid:9697050 urn:pmcid:PMC9697050 urn:oai:pubmedcentral.nih.gov:9697050 urn:oai:egreta.uab.cat:publications/ca7587e4-6175-41bc-ba8f-df62faf8cac2 eng Journal of Alzheimer's disease ; Vol. 90 Núm. 2 (2022), p. 719-726 open access Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original. https://creativecommons.org/licenses/by/4.0/ application/pdf